# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JP Morgan analyst Brian Essex maintains Cellebrite DI (NASDAQ:CLBT) with a Overweight and raises the price target from $12 t...
Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and raises the price target from $13.5 to $14.
Cellebrite DI reported strong Q1 FY24 results with revenue up 26% YoY, ARR at $331.8 million, and EPS beating consensus. Outloo...
Cellebrite DI (NASDAQ:CLBT) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $0.06 b...
Lake Street analyst Frank Takkinen initiates coverage on Cellebrite DI (NASDAQ:CLBT) with a Buy rating and announces Price T...
Craig-Hallum analyst Jeff Van Rhee maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and raises the price target from $14 to ...
B of A Securities analyst Tal Liani maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and raises the price target from $12 to...